This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Davis, T. M. Articles by Batty, K. T Search for Related Content Social Bookmarking                         What's this?

The role of pharmaceutical care in diabetes management

School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Australia, tdavis{at}cyllene.uwa.edu.au

Rhonda M Clifford

School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia, Nedlands, Australia

Wendy A Davis

School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Australia

Kevin T Batty

School of Pharmacy, Curtin University of Technology, Bentley, Australia

Pharmaceutical care (PC) is a process through which a pharmacist works with other healthcare professionals and the patient to optimise pharmacotherapy. Early studies, carried out before PC was established, provided limited evidence of the benefits of pharmacist involvement in diabetes management. More recent research has examined the role of PC in a range of diabetic sub-groups. Although few of these studies were randomised, prospective and included clinically important end points such as HbA1C, some beneficial effects of PC were reported. In the most recent study, a 12-month randomised controlled trial of PC in community-based diabetic patients, regular face-to-face and telephone interviews with an experienced clinical pharmacist improved glycosylated haemoglobin while glycaemic control did not change in the controls. In addition, reductions in blood pressure, and in absolute vascular risk for patients with no history of coronary artery disease, were significantly greater in the PC group. Available evidence suggests that PC can prove a valuable component of community-based multi-disciplinary diabetes care.

Key Words: pharmaceutical care • diabetes • vascular risk factors.

References

• Strand LM, Cipolle RJ, Morley PC Pharmaceutical care: an introduction. Kalamazoo, Michigan: Upjohn; 1992.
• Hepler CD, Strand LM Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.[Abstract]
• Knowlton CH, Thomas OV, Williamson A. et al. Establishing community pharmacy-based anticoagulation education and monitoring programs. J Am Pharm Assoc 1999;39:368-74.
• Kennie NR, Schuster BG, Einarson TR Critical analysis of the pharmaceutical care research literature. Ann Pharmacother 1998;32:17-26.[Abstract/Free Full Text]
• Sczupak CA, Conrad WF Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm 1977;34:1238-42.[Medline] [Order article via Infotrieve]
• Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm 1979;36:1321-5.[Medline] [Order article via Infotrieve]
• Jaber LA, Halapy H., Fernet M., Tummalapalli S., Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238-43.[Abstract]
• Halapy H., Jaber LA Diabetes management: follow-up. Ann Pharmacother 1997;31:371.[Web of Science][Medline] [Order article via Infotrieve]
• Coast-Senior E., Kroner B., Kelley C., Trilli L. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Am J Health Syst Pharm 1998;55:638-41.[Free Full Text]
• Baran RW, Crumlish K., Patterson H. et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counselling. Am J Health Syst Pharm 1999;56:1535-9.[Free Full Text]
• Kelly C., Rodgers PT Implementation and evaluation of a pharmacist-managed diabetes service. J Manag Care Pharm 2000;6:488-93.
• Odegard PS, Goo A., Hummel J., Williams KL, Gray SL Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother 2005;39:433-40.[Abstract/Free Full Text]
• Cooper J. Consultant pharmacist contribution to diabetes mellitus patients outcomes in two nursing facilities. Consult Pharm 1995;10:40-5.
• Veldhuizen-Scott M., Widmer L., Stacey F., Popovich N. Developing and implementing a pharmaceutical care model in an ambulatory care setting for patients with diabetes. Diab Educ 1995;21:117-23.[CrossRef]
• Wermeille J., Bennie M., Brown I., McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team - a pilot study. Pharm World Sci 2004;26:18-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cranor C., Bunting B., Christensen D. The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-84.[CrossRef]
• Irons BK, Lenz RJ, Anderson SL, Wharton B., Habeger B., Anderson G. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy 2002;22:1294-300.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Clifford RM, Batty KT, Davis TM et al. A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract 2002;10:85-9.
• Clifford RM, Batty KT, Davis WA, Davis TM Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. Diabetes Care 2005;28:771-6.[Abstract/Free Full Text]
• Davis TM, Zimmet P., Davis WA, Bruce D., Fida S., Mackay I. Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 2000;17:667-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bruce DG, Davis WA, Davis TM Glycemic control in elderly subjects with type 2 diabetes mellitus in the Fremantle Diabetes Study. J Am Geriatr Soc 2000;48:1449-53.[Web of Science][Medline] [Order article via Infotrieve]
• Stevens RJ, Kothari V., Adler AI, Stratton IM for the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001;101:671-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 6, 352-356 (2005)
DOI: 10.1177/14746514050050061001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Davis, T. M. Articles by Batty, K. T Search for Related Content Social Bookmarking                         What's this?